ATLAS Phase III Data Point Avastin/Tarceva Combo In Positive Direction
Executive Summary
Phase III results using an Avastin and Tarceva combination in non-small cell lung cancer could mean FDA will not insist on survival data before approving Tarceva's supplemental NDA in first-line maintenance non-small lung cancer
You may also be interested in...
Will Maintenance Sell In NSCLC? Experts Weigh Costs Against Benefits
Longer-term "maintenance" therapy may be the new frontier for oncology products as cancer evolves into a chronic, manageable disease – a shift that will provide benefits for patients and the pharmaceutical industry. But as cancer drug costs continue to skyrocket and cost-effectiveness discussions become more commonplace, that transition may not come as smoothly as industry would like.
Will Maintenance Sell In NSCLC? Experts Weigh Costs Against Benefits
Longer-term "maintenance" therapy may be the new frontier for oncology products as cancer evolves into a chronic, manageable disease – a shift that will provide benefits for patients and the pharmaceutical industry. But as cancer drug costs continue to skyrocket and cost-effectiveness discussions become more commonplace, that transition may not come as smoothly as industry would like.
Roche Ups Negotiating Ante With Hostile Bid For Genentech
By making a hostile bid for Genentech at a lower price, Roche is trying to address at least two important concerns in one blow: uncertainty over upcoming results of a key clinical trial for the blockbuster Avastin cancer medication and offsetting potentially higher financing costs needed to ink the deal due to the troubled economic climate